NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
NextCure (Nasdaq: NXTC) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The clinical-stage biopharmaceutical company, focused on developing novel cancer therapies, will engage in a fireside chat on Thursday, December 5, at 12:00 pm ET.
The event will feature a live audio webcast accessible through the Investors section of NextCure's website. The presentation will remain archived on the company's website for 30 days following the event.
NextCure (Nasdaq: NXTC) ha annunciato la sua partecipazione alla 36a Conferenza Annuale di Piper Sandler sulla Salute a New York City. L'azienda biofarmaceutica in fase clinica, focalizzata sullo sviluppo di nuove terapie contro il cancro, parteciperà a una conversazione informale giovedì 5 dicembre alle 12:00 ET.
L'evento presenterà un webcast audio dal vivo accessibile attraverso la sezione Investitori del sito web di NextCure. La presentazione rimarrà archiviata sul sito dell'azienda per 30 giorni successivi all'evento.
NextCure (Nasdaq: NXTC) ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler en la ciudad de Nueva York. La compañía biofarmacéutica en etapa clínica, centrada en el desarrollo de nuevas terapias contra el cáncer, participará en una charla informal el jueves 5 de diciembre a las 12:00 pm ET.
El evento contará con un webcast de audio en vivo accesible a través de la sección de Inversores del sitio web de NextCure. La presentación permanecerá archivada en el sitio de la empresa durante 30 días después del evento.
NextCure (Nasdaq: NXTC)가 뉴욕에서 열리는 제36회 파이퍼 샌들러 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 새로운 암 치료법 개발에 집중하는 임상 단계의 바이오제약 회사인 NextCure는 12월 5일 목요일 오후 12시(ET)에 파이어사이드 채팅을 진행할 예정입니다.
이번 행사에서는 NextCure 웹사이트의 투자자 섹션을 통해 접근할 수 있는 실시간 오디오 웹캐스트가 제공됩니다. 발표 내용은 행사 이후 30일 동안 회사 웹사이트에 보관됩니다.
NextCure (Nasdaq: NXTC) a annoncé sa participation à la 36ème Conférence Annuelle de Piper Sandler sur la Santé à New York. L'entreprise bio-pharmaceutique en phase clinique, qui se concentre sur le développement de nouvelles thérapies contre le cancer, participera à une discussion informelle le jeudi 5 décembre à 12h00 ET.
L'événement comprendra un webcast audio en direct accessible via la section Investisseurs du site web de NextCure. La présentation sera archivée sur le site de l'entreprise pendant 30 jours après l'événement.
NextCure (Nasdaq: NXTC) hat seine Teilnahme an der 36. jährlichen Piper Sandler Healthcare-Konferenz in New York City bekannt gegeben. Das biopharmazeutische Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Krebstherapien konzentriert, wird am Donnerstag, den 5. Dezember, um 12:00 Uhr ET an einem informellen Gespräch teilnehmen.
Die Veranstaltung wird einen live Audio-Webcast beinhalten, der über den Investorensitz von NextCures Website zugänglich ist. Die Präsentation wird für 30 Tage nach der Veranstaltung auf der Unternehmenswebsite archiviert.
- None.
- None.
BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference in New York City on Thursday, December 5, at 12:00 pm ET.
A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company that is focused on advancing innovative medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. http://www.nextcure.com
Cautionary Statement Regarding Forward-Looking Statements
Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, including that early clinical data may not be confirmed by later clinical results; risks that pre-clinical research may not be confirmed in clinical trials; risks related to marketing approval and commercialization; and NextCure’s dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
FAQ
When is NextCure (NXTC) presenting at the Piper Sandler Healthcare Conference?
How can I watch NextCure's (NXTC) presentation at the Piper Sandler Conference?
How long will NextCure's (NXTC) Piper Sandler Conference presentation be available online?
What type of presentation will NextCure (NXTC) give at the Piper Sandler Healthcare Conference?
